Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
Business Wire•26/10/2026•09:45 ET
0
Key Highlights
- ➤INCB161734 plus mFOLFIRINOX achieved 89% confirmed-plus-pending ORR and 100% DCR in PDAC
- ➤INCB161734 plus cetuximab delivered 36% ORR and 7.2-month median PFS in advanced CRC
- ➤INCA33890 plus FOLFOX and bevacizumab produced 71% ORR and 81% six-month PFS in first-line MSS CRC
- ➤DAWN-302 Phase 3 study of INCB161734 plus cetuximab expected to begin in first-half 2027
- ➤Incyte plans Phase 1b PDAC collaborations with Bristol Myers Squibb and Synnovation
Expert Statements
Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte
“At Incyte we are focused on improving outcomes for people living with cancer. The data presented for INCB161734 and INCA33890 show the potential of both programs to improve the standard-of-care in hard-to-treat diseases.”
Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte
“Across pancreatic and colorectal cancers, we continue to see encouraging evidence of clinical activity and manageable safety profiles, supporting the promise of these programs across tumor types and lines of therapy. Together, INCB161734 and INCA33890 are emerging as the foundation of our growing solid tumor portfolio, with the potential to address significant patient needs.”
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
INCB161734 (KRAS G12D inhibitor) and INCA33890(1) (TGFβR2×PD-1 bispecific antibody) data reinforce ongoing and planned registrational trials, including DAWN-303 in pancreatic ductal adenocarcinoma (PDAC) and NEXERA-303 in colorectal cancer (CRC), respectively
Get started
Create a free account to read the full story.